Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
August 27, 2021
Company name
Shin Nippon Biomedical Laboratories, Ltd.
Representative
Representative Chairman, President & CEO
Ryoichi Nagata
Listing
TSE first section: ticker code 2395
Inquiries
Senior Officer & Senior Director,
Corporate Communications, Toshiyuki Iwata
TEL
+81 3 5565 6216
Notice Regarding Establishment of SDGs Committee
Shin Nippon Biomedical Laboratories, Ltd. (hereinafter, "SNBL") is pleased to announce that the board of the company resolved to establish a Sustainable Development Goals ("SDGs") Committee, an arbitrarily-formed advisory body to the board of directors today. The Committee allows further systematic reinforcement and promotion in the company-wide sustainability management efforts from mid- and long-term perspectives.
The SDGs Committee is chaired by Professor Keiko Toya who is SNBL's external director. She is also a member of a special-interest group on "SDGs and Practices, Theories and Education of Business Administration" of Specialty Committee of Business Administration, the Science Council of Japan (SCJ). The SDGs Committee consists of 5 members who are officers and representatives of various business departments, of which 40% are female. Under the SDGs Committee, working groups will be set up to address and discuss individual ESG (environmental, social, and governance) issues in order to exhaustively and flexibly undertake a broad range of sustainability efforts overall, such as formulating group-wide basic policies and goals, building and improving necessary frameworks, and promoting and monitoring the implementation of related measures, to support SNBL's sustainable growth.
Vowing to "Value the Environment, Life, and People" as stated in its corporate philosophy and with its unique slogan of "I'm Happy, You're Happy, and Everybody's Happy", SNBL has always been proactively engaged in a wide range of efforts for the realization of a sustainable society.
At SNBL, we see SDGs as a global common goal set for people around the world to live happily. By reflecting various sustainable issues in SNBL's corporate strategy and through our efforts for sustainable business growth in the medium and long term, we will continue to prove our commitment to the realization of a society where all stakeholders can live happily.
END
Attachments
Original document
Permalink
Disclaimer
Shin Nippon Biomedical Laboratories Ltd. published this content on 27 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 August 2021 08:11:16 UTC.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 
